单家私立骨科机构CPT 22修饰符应用经验:成功率、报销与财务负担
本研究回顾性分析了美国一家私立骨科集团3年内4个亚专科的18,612例手术索赔,其中2,741例(14.7%)使用了CPT 22修饰符。结果显示总体成功率为71.7%,政府支付方成功率最高(78.0%),运动医学最低(64.7%);修饰符使报销总体增加7.7%,但导致报销延迟增加39.1%至77.4%,且部分亚专科重新计费率显著升高。
要点
- CPT 22修饰符总体成功率为71.7%,政府支付方(78.0%)高于商业(65.0%)和工伤(62.9%)。
- 修饰符仅带来7.7%的报销增加,但报销延迟增加39.1%至77.4%,行政负担可能抵消财务收益。
- 运动医学成功率最低(64.7%),成人重建拒绝后重新计费率显著高于未修改索赔。
核心结论
- CPT 22修饰符在政府支付方中成功率更高,但报销增加有限,且伴随报销延迟和重新计费负担。
研究设计与样本
- 回顾性研究,分析单家美国私立骨科集团3年内4个亚专科(成人重建、手、肩、运动医学)的全部手术索赔。
主要发现
- 共纳入18,612例索赔,2,741例(14.7%)使用22修饰符,总体成功率为71.7%。
- 各亚专科成功率:运动医学64.7%、成人重建72.8%、肩73.8%、手76.3%。
- 支付方成功率:工伤62.9%、商业65.0%、政府78.0%。
- 修饰符使报销总体增加7.7%,但报销延迟增加幅度从39.1%(手)到77.4%(肩)。
- 成人重建中,修饰符索赔被拒后重新计费率显著高于未修改索赔。
临床怎么用
- 使用22修饰符前需权衡有限的报销增加与可能的报销延迟和行政负担。
- 针对不同支付方和亚专科的成功率差异,可优化修饰符的使用策略。
局限性
- 研究为单家私立骨科集团经验,结果可能无法推广至其他机构或支付环境。
- 证据等级为预后Level III,属于回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Current Procedural Terminology (CPT) 22-modifier on surgical billing is one method to denote higher surgical procedure complexity and obtain adequate surgeon compensation for increased time, skill, and effort. However, the addition of a 22-modifier can result in delays to reimbursement, variable amounts of reimbursement, and unpredictable success of modifier approval. This study sought to investigate a single U.S. private-practice group's experience with 22-modifier success across multiple orthopaedic surgical subspecialties. METHODS: All surgical claims during a 3-year period across 4 surgical subspecialties (adult reconstruction, hand, shoulder, and sports medicine) were reviewed. The use of a 22-modifier amendment, payer, reimbursement amount, days to payment, and rebilling rate were collected for all claims. The data were analyzed to depict overall claim success and the variability that existed on the basis of payer status and subspecialty service. RESULTS: A total of 18,612 claims were included, of which 2,741 (14.7%) were amended with a 22-modifier. The overall success rate of amended claims was 71.7%. By subspecialty, sports medicine had the lowest success rate (64.7%), followed by adult reconstruction (72.8%), shoulder (73.8%), and hand (76.3%). The success rate was 62.9% for Workers' Compensation, 65.0% for commercial, and 78.0% for government payers, and the modifier resulted in a 7.7% increase in reimbursement overall. Significant delays in reimbursement were seen after claims with a 22-modifier compared with unmodified claims, with increases in time until reimbursement ranging from 39.1% (hand) to 77.4% (shoulder). Claim denial also resulted in a significantly higher rebilling rate than for unmodified claims in adult reconstruction. CONCLUSIONS: The 22-modifier was more often successfully approved by government payers than by other payers, but resulted in marginal increases in reimbursement, variable approval rates, delays to reimbursement, and increased claim rebilling rates across various orthopaedic subspecialties. The financial gain may be offset by the increased administrative work and billing burden in some procedures or subspecialties. LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Pfeil AN, Jennewine B, Sketchler B, et al. The CPT 22-Modifier at a Single Private-Practice Orthopaedic Institution: Success, Reimbursement, and Financial Burden. J Bone Joint Surg Am. 2026. PMID: 42766661. doi:10.2106/JBJS.26.00089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。